Complement Inactivator Proteins

Accession Number

DBCAT002770

Description

Serum proteins that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host. The complement system is tightly regulated by inactivators that accelerate the decay of intermediates and certain cell surface receptors.

Drugs

Drug	Drug Description
Human C1-esterase inhibitor	A C1 inhibitor used to prevent angioedema attacks associated with hereditary angioedema.
Ravulizumab	A monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.
Pegcetacoplan	A complement inhibitor indicated in the treatment of adults with paroxysmal nocturnal hemoglobinuria.
Conestat alfa	A recombinant C1INH used for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults.
Avacincaptad pegol	An RNA aptamer inhibiting the complement C5 indicated for the treatment of geographic atrophy secondary to age-related macular degeneration.

Drugs & Drug Targets

Drug	Target	Type
Human C1-esterase inhibitor	Complement C1r subcomponent	target
Human C1-esterase inhibitor	Complement C1s subcomponent	target
Human C1-esterase inhibitor	Plasma kallikrein	target
Human C1-esterase inhibitor	Coagulation factor XII	target
Human C1-esterase inhibitor	Prothrombin	target
Human C1-esterase inhibitor	Coagulation factor XI	target
Human C1-esterase inhibitor	Tissue-type plasminogen activator	target
Ravulizumab	Complement C5	target
Pegcetacoplan	Complement C3	target
Conestat alfa	Complement C1r subcomponent	target
Conestat alfa	Complement C1s subcomponent	target
Conestat alfa	Plasma kallikrein	target
Conestat alfa	Coagulation factor XII	target
Conestat alfa	Prothrombin	target
Conestat alfa	Coagulation factor XI	target
Conestat alfa	Tissue-type plasminogen activator	target
Avacincaptad pegol	Complement C5	target